The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Evaluating Overall Survival and Competing Risks of Death in Patients With Localized Renal Cell Carcinoma Using a Comprehensive Nomogram
Open accessAbstract
Purpose: Many patients with localized node-negative renal cell carcinoma (RCC) are elderly with competing comorbidities. Their overall survival benefit after surgical treatment is unknown. We reviewed cases in the Surveillance, Epidemiology, and End Results (SEER) database to evaluate the impact of kidney cancer versus competing causes of death in patients with localized RCC and develop a comprehensive nomogram to quantitate survival differences. Methods: We identified individuals with localized, surgically treated clear-cell, papillary, or chromophobe RCC in SEER (1988 through 2003). We used Fine and Gray competing risks proportional hazards regressions to predict 5-year probabilities of three competing mortality outcomes: kidney cancer death, other cancer death, and noncancer death. Results: We identified 30,801 cases of localized RCC (median age, 62 years; median tumor size, 4.5 cm). Five-year probabilities of kidney cancer death, other cancer death, and noncancer death were 4%, 7%, and 11%, respectively. Age was strongly predictive of mortality and most predictive of nonkidney cancer deaths (P < .001). Increasing tumor size was related to death from RCC and inversely related to noncancer deaths (P < .001). Racial differences in outcomes were most pronounced for nonkidney cancer deaths (P < .001). Men were more likely to die than women from all causes (P < .002). This nomogram integrates commonly available factors into a useful tool for comparing competing risks of death. Conclusion: Management of localized RCC must consider competing causes of mortality, particularly in elderly populations. Effective decision making requires treatment trade-off calculations. We present a tool to quantitate competing causes of mortality in patients with localized RCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Murray, T., & Thun, M. J. (2008) · CA: A Cancer Journal for Clinicians · doi:10.3322/ca.2007.0010 · Cited by 10,188
Harrell, F. E. (2001) · Springer Series in Statistics · doi:10.1007/978-1-4757-3462-1 · Cited by 9,195
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Rising Incidence of Renal Cell Cancer in the United States
Chow, W.-H. (1999) · JAMA · doi:10.1001/jama.281.17.1628 · Cited by 1,586
FRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2002) · Journal of Urology · doi:10.1016/s0022-5347(05)64153-5 · Cited by 1,175
Rising Incidence of Small Renal Masses: A Need to Reassess Treatment Effect
Hollingsworth, J. M., Miller, D. C., Daignault, S., & Hollenbeck, B. K. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj362 · Cited by 1,173
Solid Renal Tumors: An Analysis of Pathological Features Related to Tumor Size
FRANK, I., BLUTE, M. L., CHEVILLE, J. C., LOHSE, C. M., WEAVER, A. L., & ZINCKE, H. (2003) · Journal of Urology · doi:10.1097/01.ju.0000095475.12515.5e · Cited by 1,080
A POSTOPERATIVE PROGNOSTIC NOMOGRAM FOR RENAL CELL CARCINOMA
KATTAN, M. W., REUTER, V., MOTZER, R. J., KATZ, J., & RUSSO, P. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)66077-6 · Cited by 754
Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience
Patard, J.-J., Leray, E., Rioux-Leclercq, N., Cindolo, L., Ficarra, V., Zisman, A., De La Taille, A., Tostain, J., Artibani, W., Abbou, C. C., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.055 · Cited by 754
Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System
Zisman, A., Pantuck, A. J., Dorey, F., Said, J. W., Shvarts, O., Quintana, D., Gitlitz, B. J., deKernion, J. B., Figlin, R. A., & Belldegrun, A. S. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1649 · Cited by 729
Albertsen, P. C. (1998) · JAMA · doi:10.1001/jama.280.11.975 · Cited by 717
Zisman, A., Pantuck, A. J., Wieder, J., Chao, D. H., Dorey, F., Said, J. W., deKernion, J. B., Figlin, R. A., & Belldegrun, A. S. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.05.111 · Cited by 675
Multi-Institutional Validation of a New Renal Cancer–Specific Survival Nomogram
Karakiewicz, P. I., Briganti, A., Chun, F. K.-H., Trinh, Q.-D., Perrotte, P., Ficarra, V., Cindolo, L., De La Taille, A., Tostain, J., Mulders, P. F. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1218 · Cited by 536
The Autopsy as a Measure of Accuracy of the Death Certificate
Kircher, T., Nelson, J., & Burdo, H. (1985) · New England Journal of Medicine · doi:10.1056/nejm198511143132005 · Cited by 527
Excise, Ablate or Observe: The Small Renal Mass Dilemma—A Meta-Analysis and Review
Kunkle, D. A., Egleston, B. L., & Uzzo, R. G. (2008) · Journal of Urology · doi:10.1016/j.juro.2007.11.047 · Cited by 517
Self-citationCryoablation or radiofrequency ablation of the small renal mass: A meta‐analysis
Kunkle, D. A., & Uzzo, R. G. (2008) · Cancer · doi:10.1002/cncr.23896 · Cited by 409
Self-citationHollingsworth, J. M., Miller, D. C., Daignault, S., & Hollenbeck, B. K. (2007) · Cancer · doi:10.1002/cncr.22600 · Cited by 275
Using Protein Expressions to Predict Survival in Clear Cell Renal Carcinoma
Kim, H. L., Seligson, D., Liu, X., Janzen, N., Bui, M. H. T., Yu, H., Shi, T., Figlin, R. A., Horvath, S., & Belldegrun, A. S. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0488 · Cited by 233
Walz, J., Gallina, A., Saad, F., Montorsi, F., Perrotte, P., Shariat, S. F., Jeldres, C., Graefen, M., Bénard, F., McCormack, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.3820 · Cited by 220
FRANK, I., BLUTE, M. L., LEIBOVICH, B. C., CHEVILLE, J. C., LOHSE, C. M., & ZINCKE, H. (2005) · Journal of Urology · doi:10.1097/01.ju.0000158043.94525.d6 · Cited by 220
USING TUMOR MARKERS TO PREDICT THE SURVIVAL OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
KIM, H. L., SELIGSON, D., LIU, X., JANZEN, N., BUI, M. H. T., YU, H., SHI, T., BELLDEGRUN, A. S., HORVATH, S., & FIGLIN, R. A. (2005) · Journal of Urology · doi:10.1097/01.ju.0000154351.37249.f0 · Cited by 216
Katz, M. D. (2008) · Yearbook of Urology · doi:10.1016/s0084-4071(08)79028-6 · Cited by 171
Preoperative Nomogram Predicting 12-Year Probability of Metastatic Renal Cancer
Raj, G. V., Thompson, R. H., Leibovich, B. C., Blute, M. L., Russo, P., & Kattan, M. W. (2008) · The Journal of Urology · doi:10.1016/j.juro.2008.01.101 · Cited by 126
A competing‐risks nomogram for sarcoma‐specific death following local recurrence
Kattan, M. W., Heller, G., & Brennan, M. F. (2003) · Statistics in Medicine · doi:10.1002/sim.1574 · Cited by 106
Survival Analysis of Clear Cell Renal Carcinoma According to the Charlson Comorbidity Index
Arrontes, D. S., Fernández‐Aceñero, M. J., González, J. I. G., Muñoz, M. P. M., & Andrés, P. P. (2008) · The Journal of Urology · doi:10.1016/j.juro.2007.10.048 · Cited by 90
Gettman, M. T., Boelter, C., Cheville, J. C., Zincke, H., Bryant, S. C., & Blute, M. L. (2003) · The Journal of Urology · doi:10.1097/01.ju.0000049093.03392.cc · Cited by 86
Adjuvant therapy for high-risk renal cell carcinoma patients
Kunkle, D. A., Haas, N. B., & Uzzo, R. G. (2007) · Current Urology Reports · doi:10.1007/s11934-007-0017-5 · Cited by 28
Self-citationEgleston, B. L., & Wong, Y. (2009) · Statistics in Medicine · doi:10.1002/sim.3557 · Cited by 9
Self-citation
Cited by
Capitanio, U., & Montorsi, F. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00046-x · Cited by 1,014
Why Summary Comorbidity Measures Such As the Charlson Comorbidity Index and Elixhauser Score Work
Austin, S. R., Wong, Y.-N., Uzzo, R. G., Beck, J. R., & Egleston, B. L. (2015) · Medical Care · doi:10.1097/mlr.0b013e318297429c · Cited by 716
Self-citationSmaldone, M. C., Kutikov, A., Egleston, B. L., Canter, D. J., Viterbo, R., Chen, D. Y. T., Jewett, M. A., Greenberg, R. E., & Uzzo, R. G. (2012) · Cancer · doi:10.1002/cncr.26369 · Cited by 405
Self-citationManagement of Small Renal Masses: American Society of Clinical Oncology Clinical Practice Guideline
Finelli, A., Ismaila, N., Bro, B., Durack, J., Eggener, S., Evans, A., Gill, I., Graham, D., Huang, W., Jewett, M. A. S., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.69.9645 · Cited by 367
Self-citationPrognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
Sun, M., Shariat, S. F., Cheng, C., Ficarra, V., Murai, M., Oudard, S., Pantuck, A. J., Zigeuner, R., & Karakiewicz, P. I. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.041 · Cited by 325
Metadata
- Authors
- Kutikov, A., Egleston, B. L., Wong, Y.-N., & Uzzo, R. G.
- Venue
- Journal of Clinical Oncology
- Published
- 2010-01-10
- Volume
- 28
- Issue
- 2
- Pages
- 311-317
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2145113844
- Cited by
- 292
- References
- 29
- FWCI
- 16.01
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.